7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Pregnancy Complications, Hematologic D011250 11 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Venous Thrombosis D020246 11 associated lipids
Thinness D013851 11 associated lipids
Myocardial Ischemia D017202 11 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Osteoporosis D010024 12 associated lipids
Hypocalcemia D006996 12 associated lipids
Disease Susceptibility D004198 12 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Polycythemia Vera D011087 13 associated lipids
Stomatitis D013280 14 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Angina, Unstable D000789 14 associated lipids
Synovitis D013585 15 associated lipids
Carotid Stenosis D016893 15 associated lipids
Periodontal Diseases D010510 15 associated lipids
Encephalitis D004660 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Celiac Disease D002446 16 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Brain Infarction D020520 17 associated lipids
Albuminuria D000419 18 associated lipids
Carcinoma D002277 18 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Wounds and Injuries D014947 20 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
HIV Infections D015658 20 associated lipids
Cachexia D002100 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Periodontitis D010518 22 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Endometriosis D004715 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Obesity D009765 29 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Diarrhea D003967 32 associated lipids
Hypothyroidism D007037 32 associated lipids
Uremia D014511 33 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Heart Failure D006333 36 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Arthritis D001168 41 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Osteosarcoma D012516 50 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nerve Degeneration D009410 53 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Weight Loss D015431 56 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Coronary Disease D003327 70 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Leukemia D007938 74 associated lipids
Alzheimer Disease D000544 76 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Atherosclerosis D050197 85 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Arteriosclerosis D001161 86 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Insulin Resistance D007333 99 associated lipids
Weight Gain D015430 101 associated lipids
Glioma D005910 112 associated lipids
Hypertension D006973 115 associated lipids
Inflammation D007249 119 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Adenocarcinoma D000230 166 associated lipids
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Saika M et al. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. 2001 Endocrinology pmid:11356664
Mackie PS et al. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. 2001 Br. J. Cancer pmid:11286476
Hofbauer LC et al. Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. 2001 J. Rheumatol. pmid:11327234
Hofbauer LC and Heufelder AE The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. 2001 Arthritis Rheum. pmid:11229454
Leach RJ et al. The genetics of Paget's disease of the bone. 2001 J. Clin. Endocrinol. Metab. pmid:11231972
Luger NM et al. Osteoprotegerin diminishes advanced bone cancer pain. 2001 Cancer Res. pmid:11358823
Haynes DR et al. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. 2001 Rheumatology (Oxford) pmid:11426018
Szulc P et al. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. 2001 J. Clin. Endocrinol. Metab. pmid:11443182
Sakiyama H et al. Establishment and characterization of macrophage-like cell lines expressing osteoclast-specific markers. 2001 J. Bone Miner. Metab. pmid:11448014
Choi Y et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. 2001 Eur. J. Immunol. pmid:11449372
Kanzaki H et al. Dual regulation of osteoclast differentiation by periodontal ligament cells through RANKL stimulation and OPG inhibition. 2001 J. Dent. Res. pmid:11379890
Hein GE [Pathophysiology of bone loss in rheumatic diseases--do bone markers help in monitoring?]. 2001 Z Rheumatol pmid:11383046
Morony S et al. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. 2001 Cancer Res. pmid:11389072
Kim KJ et al. Osteoprotegerin inhibits in vitro mouse osteoclast formation induced by joint fluid from failed total hip arthroplasty. 2001 J. Biomed. Mater. Res. pmid:11410897
Abu-Amer Y IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. 2001 J. Clin. Invest. pmid:11390419
Kon T et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. 2001 J. Bone Miner. Res. pmid:11393777
Fazzalari NL et al. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. 2001 J. Bone Miner. Res. pmid:11393778
Bekker PJ et al. The effect of a single dose of osteoprotegerin in postmenopausal women. 2001 J. Bone Miner. Res. pmid:11204435
Thirunavukkarasu K et al. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. 2001 J. Biol. Chem. pmid:11451955
Yun TJ et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. 2001 J. Immunol. pmid:11160187
Stejskal D et al. Osteoprotegerin, RANK, RANKL. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426773
Stejskal D et al. Osteoprotegerin and bone density. 2001 Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub pmid:12426776
Takemura M et al. Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee. 2001 Metab. Clin. Exp. pmid:11172466
Gravallese EM et al. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. 2001 Arthritis Res. pmid:11178122
Makiishi-Shimobayashi C et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. 2001 Biochem. Biophys. Res. Commun. pmid:11181055
Wada N et al. Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. 2001 J. Periodont. Res. pmid:11246705
Jung K et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. 2001 Clin. Chem. pmid:11673385
Lean JM et al. FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. 2001 Blood pmid:11675341
Fiumara P et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. 2001 Blood pmid:11675352
Satoh K et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. 2001 Pancreas pmid:11590320
Yano K et al. Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF): possible role of OPG/OCIF in the prevention of osteoporosis in pregnancy. 2001 Biochem. Biophys. Res. Commun. pmid:11594776
Brown JM et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. 2001 Clin. Cancer Res. pmid:11595685
Price PA et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11597934
Nemec K and Schubert-Zsilavecz M [Future therapies for metabolic bone diseases. New concepts and targets]. 2001 Pharm Unserer Zeit pmid:11715689
Kuntz KA et al. An immunohistochemical study of osteoprotegerin in the human dental pulp. 2001 J Endod pmid:11716077
Hofbauer LC and Schoppet M Serum measurement of osteoprotegerin--clinical relevance and potential applications. 2001 Eur. J. Endocrinol. pmid:11720890
Ueland T et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. 2001 Eur. J. Endocrinol. pmid:11720891
Chikazu D et al. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. 2001 J. Bone Miner. Res. pmid:11697804
Khosla S Minireview: the OPG/RANKL/RANK system. 2001 Endocrinology pmid:11713196
Seidel C et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. 2001 Blood pmid:11568016
Fukagawa M et al. Skeletal resistance to pth as a basic abnormality underlying uremic bone diseases. 2001 Am. J. Kidney Dis. pmid:11576943
Sato T et al. Osteoprotegerin levels before and after renal transplantation. 2001 Am. J. Kidney Dis. pmid:11576949
Furuya D et al. Immuno-PCR assay for homodimeric osteoprotegerin. 2001 Clin. Chem. pmid:11468243
Seck T et al. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. 2001 Eur. J. Endocrinol. pmid:11454517
Burguera B et al. Leptin reduces ovariectomy-induced bone loss in rats. 2001 Endocrinology pmid:11459801
Yamagishi T et al. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. 2001 Endocrinology pmid:11459812
Ma YL et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. 2001 Endocrinology pmid:11517184
Bateman TA et al. Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. 2001 J. Orthop. Res. pmid:11518255
Myoung H et al. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. 2001 J. Periodont. Res. pmid:11519698
Haynes DR et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. 2001 J Bone Joint Surg Br pmid:11521937
Hofbauer LC and Schoppet M Osteoprotegerin: a link between osteoporosis and arterial calcification? 2001 Lancet pmid:11498208
Sakai A et al. 1alpha-Hydroxyvitamin D3 suppresses trabecular bone resorption by inhibiting osteoclastogenic potential in bone marrow cells after ovariectomy in mice. 2001 J. Bone Miner. Metab. pmid:11498729
Ikeda T et al. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. 2001 J. Bone Miner. Res. pmid:11499864
Thomas GP et al. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. 2001 J. Endocrinol. pmid:11479141
Allan GF et al. Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification. 2001 Steroids pmid:11546554
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Halladay DL et al. Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. 2001 J. Cell. Biochem. pmid:11746511
Cao Y et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. 2001 Cell pmid:11747812
Chung H et al. Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. 2001 J. Korean Med. Sci. pmid:11748360
Komuro H et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. 2001 Arthritis Rheum. pmid:11762937
Lindberg MK et al. Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice. 2001 J. Endocrinol. pmid:11739008
Giuliani N et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. 2001 Blood pmid:11739153
Croucher PI et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 2001 Blood pmid:11739154
Dhore CR et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. 2001 Arterioscler. Thromb. Vasc. Biol. pmid:11742876
Ramalho AC et al. Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. 2001 Cytokine pmid:11792122
Yano K et al. Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. 2001 J. Bone Miner. Metab. pmid:11685652
Kawahara N et al. Two novel cucurbitacins, neocucurbitacins A and B, from the Brazilian folk medicine "Buchinha" (Luffa operculata) and their effect on PEBP2alphaA and OCIF gene expression in a human osteoblast-like Saos-2 cell line. 2001 Chem. Pharm. Bull. pmid:11605678
Boissy P et al. RANKL induces formation of avian osteoclasts from macrophages but not from macrophage polykaryons. 2001 Biochem. Biophys. Res. Commun. pmid:11606048
Kotake S et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. 2001 Arthritis Rheum. pmid:11352231
Yan T et al. Regulation of osteoclastogenesis and RANK expression by TGF-beta1. 2001 Aug 1-9 J. Cell. Biochem. pmid:11573248
Rosa-Rañal M et al. [New paradigms in the regulation of bone metabolism]. 2001 Jul-Aug Rev. Invest. Clin. pmid:11599485
Geoffroy V et al. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. 2002 Mol. Cell. Biol. pmid:12167715
Uemura H et al. Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. 2002 J. Endocrinol. pmid:12176675
Gruber R et al. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. 2002 Bone pmid:11996911
de Hooge AS et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. 2002 Am. J. Pathol. pmid:12000725
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Inoue D [Recent advances in research of bone resorption]. 2002 Nippon Rinsho pmid:11979946
Wittrant Y et al. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. 2002 Biochem. Biophys. Res. Commun. pmid:12054560
Penno H et al. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. 2002 Biochem. Biophys. Res. Commun. pmid:12054622
Fu M et al. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells. 2002 Biochem. Biophys. Res. Commun. pmid:12056809
Kim YH et al. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. 2002 Exp. Mol. Med. pmid:12085990
Khosla S et al. Correlates of osteoprotegerin levels in women and men. 2002 Osteoporos Int pmid:12086350
Rubin J et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. 2002 J. Clin. Endocrinol. Metab. pmid:12213884
Palmqvist P et al. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. 2002 J. Immunol. pmid:12218157
Kudo O et al. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. 2002 J. Pathol. pmid:12237882
Hofbauer LC et al. High bone density due to a mutation in LDL-receptor-related protein 5. 2002 N. Engl. J. Med. pmid:12240686
Okada Y et al. Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. 2002 Endocr. J. pmid:12402981
Ito S et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. 2002 J. Biol. Chem. pmid:11733492
Buckley KA and Fraser WD Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 Ann. Clin. Biochem. pmid:12564836
Scatena M and Giachelli C The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 Trends Cardiovasc. Med. pmid:11852256
Hofbauer LC and Kühne CA Cytokine inhibition: a new therapeutic avenue for skeletal diseases. 2002 Drug Discov. Today pmid:11854049
Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 Biochem. Biophys. Res. Commun. pmid:11855844
Romas E et al. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. 2002 Bone pmid:11856640
Viereck V et al. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 J. Cell. Biochem. pmid:11835398
Golmia RP et al. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. 2002 Arthritis Rheum. pmid:12483748
Liegibel UM et al. Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode. 2002 J. Exp. Med. pmid:12438430
Bolon B et al. Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. 2002 Cell. Mol. Life Sci. pmid:12440777
David JP et al. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. 2002 J. Cell. Sci. pmid:12376563
Jones DH et al. Role of RANKL and RANK in bone loss and arthritis. 2002 Ann. Rheum. Dis. pmid:12379618

Table of Content